Lungpacer Medical Inc.
10
1
1
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
10.0%
1 terminated/withdrawn out of 10 trials
87.5%
+1.0% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Pacing In Organ Donors (the POD Trial)
Role: collaborator
A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System
Role: lead
STimulation to Activate RespIration
Role: lead
Feasibility of Transvenous Phrenic Nerve Stimulation for Diaphragm Protection in Acute Respiratory Failure
Role: collaborator
A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation
Role: lead
Phrenic Nerve Stimulation-Induced Lung ReAeration Trial
Role: lead
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing
Role: lead
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1)
Role: lead
Percutaneous Temporary Placement of a Transvenous Phrenic Nerve Stimulator for Diaphragm Pacing Using Jugular Access
Role: lead
Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial
Role: lead
All 10 trials loaded